Answers are grounded in this paper and cite their sources.
Narrative review reveals insufficient evidence supporting cell and vesicle therapies in treatment-resistant depression, highlighting the need for structured translational frameworks.
Peer-reviewed critical narrative review from the IVURH Faculty of Regenerative Neuroscience and Neurology examining mesenchymal stromal cells (MSCs), extracellular vesicles (EVs), exosomes, and secretome-based approaches for treatment-resistant depression. The article critically evaluates preclinical mechanisms, human evidence, delivery, manufacturing, safety, biomarkers, and regulatory considerations, and proposes a translational framework separating product identity, biological activity, clinical benefit, and evidence of disease modification. Current evidence remains insufficient to establish efficacy or disease modification in unipolar treatment-resistant depression.
No takes yet. Share an insight, caveat, or question.
Rana et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: